Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) EBITDA (2016 - 2025)

Spero Therapeutics' EBITDA history spans 10 years, with the latest figure at $31.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 285.5% year-over-year to $31.4 million; the TTM value through Dec 2025 reached $6.3 million, up 109.21%, while the annual FY2025 figure was $6.3 million, 109.21% up from the prior year.
  • EBITDA reached $31.4 million in Q4 2025 per SPRO's latest filing, up from -$7.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $51.2 million in Q4 2023 to a low of -$32.8 million in Q1 2022.
  • Average EBITDA over 5 years is -$6.5 million, with a median of -$13.6 million recorded in 2023.
  • Peak YoY movement for EBITDA: crashed 480.12% in 2024, then soared 285.5% in 2025.
  • A 5-year view of EBITDA shows it stood at -$29.2 million in 2021, then soared by 191.56% to $26.8 million in 2022, then soared by 91.22% to $51.2 million in 2023, then plummeted by 133.07% to -$16.9 million in 2024, then skyrocketed by 285.5% to $31.4 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's EBITDA are $31.4 million (Q4 2025), -$7.9 million (Q3 2025), and -$2.4 million (Q2 2025).